SAMDI Tech, Inc and Exquiron Announce Partnership Agreement
News Feb 27, 2015
SAMDI Tech and Exquiron are expanding their service offering by entering into a partnership agreement, allowing SAMDI Tech and Exquiron to mutually promote their respective services in Europe and North America. The two companies aim to offer hit discovery, hit profiling, and assay development services, combining their expertise to the benefit of their clients. The partnership provides SAMDI Tech’s clients the added benefit of Exquiron’s broad assay capabilities and lead-like, 250,000 compound collection as well as access of SAMDI Tech’s exclusive label-free, MALDI-TOF capabilities to Exquiron and its clients.
“I am excited to partner with Exquiron as our technology is innovative to the discovery field and coupled with Exquiron’s additional assay capabilities and compound collection we can offer a comprehensive solution to our clients.” said Emilio Córdova Ph.D., MBA, CEO at SAMDI Tech.
SAMDI is a unique label-free assay platform for measurement of complex biochemical activity.
Stephan Fasler Ph.D., CEO of Exquiron commented “We have previously collaborated with SAMDI Tech; the company has been our first choice for entering into this partnership. We are impressed by the novelty and quality of SAMDI Tech’s label-free assay technology, which, coupled with their excellent assay development services, renders SAMDI Tech a company to absolutely work with.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019